NEWS RELEASE

NYSE American to Commence Delisting Proceedings Against BioPharmX Corporation (BPMX)

3/24/2020

NEW YORK, March 24, 2020 – NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of BioPharmX Corporation (the "Company") — ticker symbol "BPMX" — from the Exchange.

In reaching its decision, Staff determined in accordance with Section 1009(a) of the NYSE American Company Guide (the "Company Guide") that it is necessary and appropriate for the protection of investors to initiate delisting proceedings because the Company did not cure its non-compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18 month compliance plan period, which expired on March 24, 2020.

The Company has a right to a review of staff's determination to delist the common stock by a committee of the Board of Directors of the Exchange (the "Committee"). Following such appeal, a decision by the Committee will be made and announced by NYSE Regulation regarding either proceeding with suspension and delisting or continued trading in the Company's common stock. If the Company does not appeal this determination, NYSE American will announce the date that trading will be suspended. The filing of an application with the Securities and Exchange Commission to delist the common stock is pending completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

Company Contact:
Investor and Media Contact, **investors@biopharmx.com**